Search Frequenty Asked Questions

Normal Fonts Larger Fonts Printer Version Email this page Submit Feedback Questions & Answers About CMS Return to cms.hhs.gov Home Normal Fonts Larger Fonts Email this page Submit Feedback Questions & Answers About CMS Return to cms.hhs.gov Home
Return to cms.hhs.gov Home    Return to cms.hhs.gov Home

  


  Professionals   Governments   Consumers   Public Affairs
Programs
Topics
Resources

Medicare Coverage Database

Medicare Coverage home page coverage home | view page help help | view basket basket   
 
tab imageSearchtab imageIndexestab imageReportstab imageDownloadtab image 
 

Indexes Home > National Coverage Analyses (NCAs) > View NCA

NCA for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R3)

 
 Contacts

Marc Stone, MD
mstone@cms.hhs.gov
1-410-786-6694

Stuart Caplan, RN, MAS
scaplan@cms.hhs.gov
1-410-786-8564


 
 Documents
Tracking Sheet

MCAC Meetings

Decision Memo

 
 History of Considerations
First reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R)

Second reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R2)

Third reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (this document)

Original consideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066N)


basket Add to basket  |  email Email this to a friend  |  new search New Search
Department of Health and Human Services Logo
www4		 Privacy & Security | Accessibility | FOIA | Help | Email Updates | CMS Careers
Health and Human Services | Medicare.gov | FirstGov
Equal Employment Opportunity Data Posted Pursuant to the No Fear Act
CMS Identity Mark
Centers for Medicare & Medicaid Services

7500 Security Boulevard, Baltimore MD 21244-1850
CMS Telephone Numbers